Related Experiment Video

Updated: May 25, 2026

Surgical Models of Gastroesophageal Reflux with Mice
05:19

Surgical Models of Gastroesophageal Reflux with Mice

Published on: August 25, 2015

Effects of proton pump inhibitors on pediatric inflammatory esophagogastric polyps

Kyong Eun Choi1, Mi Jin Kim, Ji Hyuk Lee

  • 1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Digestion
|January 18, 2012
PubMed

Insights

Proton pump inhibitors effectively treat pediatric inflammatory esophagogastric polyps (IEPs). About five months of lansoprazole is adequate, though over seven months may be optimal for complete polyp resolution.

Area of Science:

  • Pediatric Gastroenterology
  • Pharmacological Interventions
  • Gastrointestinal Pathology

Background:

  • Investigating proton pump inhibitors (PPIs) for symptomatic inflammatory esophagogastric polyps (IEPs) in children.
  • Determining the optimal treatment duration for pediatric IEPs using PPIs.

Observation:

  • Eleven pediatric patients with IEPs were treated with lansoprazole.
  • Endoscopic follow-ups at 2 and 6 months assessed polyp size and symptom resolution.
  • Treatment cessation criteria included symptom resolution and >50% polyp size reduction.

Findings:

  • Initial polyp size averaged 13.7 mm, reducing to 8.0 mm at 2 months and 4.7 mm at 6 months.
  • Mean treatment duration was 4.8 months, with a significant linear correlation between treatment duration and polyp size reduction (p < 0.001).
  • Calculations suggest over 7 months of treatment may be optimal for complete IEP resolution.

Implications:

  • Proton pump inhibitors demonstrate efficacy in treating pediatric inflammatory esophagogastric polyps.
  • Lansoprazole treatment for approximately 5 months appears sufficient for many pediatric cases.
  • Further research into the optimal duration exceeding 7 months could enhance complete polyp resolution rates.
Abstract

More Related Videos

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease I: Introduction01:25

Peptic Ulcer Disease I: Introduction

Peptic ulcer disease (PUD) involves breaks in the gastrointestinal tract's mucosal lining, primarily in the stomach and duodenum, with less frequent occurrences in the lower esophagus or near the pylorus.Ulcers can be acute or chronic. Acute ulcers are short-lived with minimal inflammation and heal quickly after the irritant is removed. Chronic ulcers persist, may recur, and often cause scarring due to ongoing tissue damage. Superficial erosions affect only the mucosal layer and are called...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...